Status epilepticus (SE) is a life-threatening neurological emergency associated with a high mortality rate. The serotonin 1A (5-HT 1A ) receptor is a possible target for the treatment of SE, but its role in animal models and the precise area of brain involved remain controversial. The hippocampus is a candidate site due to its key role in the development of SE and the existence of a high density of 5-HT 1A receptors. Therefore, we investigated the effects of subcutaneous and intrahippocampal activation of 5-HT 1A receptors in lithium-pilocarpine-induced SE, and tested whether the hippocampus is a true effector site. We developed SE in male Sprague-Dawley rats by giving lithium chloride (LiCl; 3 meq/kg, i.p.) 22-24 h prior to pilocarpine (25 mg/kg, i.p.), and found that 8-OH-DPAT, a 5-HT 1A receptor agonist administered subcutaneously (s.c.) at 0.5 or 1.0 mg/kg 1 h before pilocarpine injection increased the latency to the fi rst epileptiform spikes, the electrographic SE, and the behavioral generalized seizures (GS), while reducing the total EEG seizure time (P <0.01). The duration of GS was shortened only by 1.0 mg/kg 8-OH-DPAT s.c. (P <0.05). All these effects were inhibited by combined administration of WAY-100635 (1.0 mg/kg, s.c.) (P <0.05), an antagonist of the 5-HT 1A receptor, but WAY-100635 alone and low doses of 8-OH-DPAT (0.01 and 0.1 mg/kg) did not alter seizure activity. Furthermore, intrahippocampal 8-OH-DPAT only shortened the GS duration (P <0.05). These fi ndings imply that the 5-HT 1A receptor is a promising therapeutic target against the generation and propagation of SE, and hippocampal receptors are involved in reducing the seizure severity.
INTRODUCTION
Status epilepticus (SE) is a common, life-threatening neurological emergency with a high mortality rate of 20% [1] . Prolonged SE can cause permanent neurological damage that contributes to severe cognitive and behavior impairments [2, 3] . The fundamental mechanisms involve persistent, excessive excitation and the failure of inhibitory recruitment from areas adjacent to the epileptogenic zone, which normally isolate and stop seizure activity spontaneously [4, 5] .
Serotonin (5-hydroxytryptamine, 5-HT) is a monoamine neurotransmitter that mediates many physiological and pathological conditions [6] . The potential link between serotonin and the inhibition of epilepsy was fi rst proposed by Bonnycastle in 1957 [7] . More recently, Trindade-Filho et al. reported that depletion of serotonin increases the incidence of SE induced by pilocarpine [8] . Moreover, a number of studies have suggested that the anticonvulsant effect of serotonin is mediated via the serotonin 1A receptor (5-HT 1A receptor) [9] [10] [11] [12] [13] , which might be a target for the treatment of SE. Despite the theoretical inhibitory effect of the 5-HT 1A receptor against seizures, the effects of its activation in animal models of SE remain controversial.
Activation of the 5-HT 1A receptor by its agonist 8-hydroxyl- 2-(di-n-propylamino)tetralin HBr (8-OH-DPAT) has anticonvulsant effects in SE induced by kainic acid (KA) [5, 12, 14] , but does not reduce the severity of seizures induced by pilocarpine (400 mg/kg, intraperitoneal, i.p.) at a relatively high dose (1.0 mg/kg) [15] . It is interesting that a high dose of 8-OH-DPAT (1.0 mg/kg) has an anticonvulsant effect, while a low dose (0.01 mg/kg) has a pro-convulsant effect in a KA model [12] . These opposing effects could be attributed to the differences in types and locations of 5-HT 1A receptor activated.
Further, it remains unclear which parts of the brain are involved in the anti-or pro-convulsant effects of 5-HT 1A receptors in SE. The hippocampus is a candidate site, due to its important role in the generation and maintenance of SE [4, 16, 17] . Furthermore, the hippocampus has a high density of 5-HT 1A receptors in the stratum radiatum of CA1 and the granule cell layer of the dentate gyrus, and a moderate level in the CA3 area. In a rat model of seizures induced by KA, activation of the 5-HT 1A receptor distributed adjacent to the focal hippocampal epileptogenic lesion has an inhibitory effect, which adds to the claim that the hippocampus may be a true effector site [14] . However, no further evidence from other SE models supports this hypothesis.
Compared with KA, untreated lithium (Li)-pilocarpineinduced SE is associated with high rates of mortality and an early onset of damage at 2.5 h after the beginning of SE in broad regions of brain, the neocortex, hippocampus, entorhinal cortex (EC), amygdala, and hypothalamus [16, [18] [19] [20] .
Therefore, the Li-pilocarpine-induced model of SE might be appropriate as it mimics the severe damage caused by prolonged SE in humans. Therefore, in this study, we used the Li-pilocarpine rat model to investigate whether the activation of 5-HT 1A receptors has an inhibitory effect on SE.
The main aim of this study was to investigate the effect of 5-HT 1A receptor activation on Li-pilocarpine-induced SE, to test whether different doses of agonist have opposite effects, and to assess whether the 5-HT 1A receptors in the hippocampus may be a target for SE therapy. at the same site as the control.
MATERIALS AND METHODS

Animals
Stereotaxic Surgery
After rats were anesthetized with pentobarbital sodium (45 mg/kg, i.p.; Sigma) and mounted on a stereotaxic apparatus (512600; Stoelting, Wood Dale, IL). They were implanted with a guide cannula (62003; RWD Life Science, Shenzhen, China) on each side (AP = -3.5 mm, L = ±2.5 mm, and V = -2.9 mm) [14] for the intrahippocampal infusion of drugs. Stainless steel screws were placed over the frontal cortex bilaterally and connected to a miniature receptacle for electroencephalogram (EEG) recordings.
The rats that received the subcutaneous drugs were only implanted with stainless-steel screws. All animals were housed individually after surgery and were allowed to recover for 7-10 days.
Status Epilepticus and EEG Recordings
Animals received an i.p. injection of lithium chloride (LiCl, 3 meq/kg, Sigma), followed by pilocarpine (25 mg/kg, i.p., Alfa Aesar) 22-24 h later. Methylscopolamine bromide
(1 mg/kg, i.p., Sigma) was injected 30 min before the pilocarpine injection to limit its peripheral effects. Diazepam (5 mg/kg, i.p., Sigma) was given 90 min after the onset of SE. Seizure severity was classifi ed according to the Racine scale [21] . [5] : the latency to the first epileptiform spike (amplitude >2-fold of baseline and duration >3 s), the latency to the onset of electrographic SE (continuous high-amplitude polyspike activity), and the total time of seizure activity according to the EEG (total EEG recording time minus interictal time).
Statistical Analysis
All data are presented as mean ± SEM. All tests were twosided and statistical signifi cance was assigned as P <0.05. 
RESULTS
Effect of Subcutaneous Administration of 8-OH-DPAT and WAY-100635
Rats were motionless 5-10 min after pilocarpine administration, and subsequently presented oro-facial movements, eye-blinking, and twitching of the vibrissae.
Following discontinuous seizures, they displayed forelimb clonus, rearing, and falling, and finally developed SE.
The SE incidence and acute mortality rates are shown in Fig. 1 . No signifi cant differences were found in these two parameters (P >0.05).
In the PBS group, the fi rst epileptiform spike occurred at 18.8 ± 1.1 min and SE at 26.8 ± 1.8 min on the EEG recordings (Fig. 2) . The total duration of the EEG seizure activity was 99.1 ± 1. Fig. 3B ), GS latency (P <0.05, Fig. 3C ), and GS duration (P <0.05, Fig. 3D ). However, WAY-100635 administration alone did not cause any signifi cant changes.
Effect of Intrahippocampal Administration of 8-OH-DPAT
Among the 24 rats administered pilocarpine, 3 out of 15 rats in the 8-OH-DPAT group failed to develop SE, whereas all the 9 rats in the control group developed SE (P >0.05).
Among the 21 rats with SE, 4/12 in the 8-OH-DPAT group and 1/9 in the PBS group were excluded from the study after sacrification as they had developed a hippocampal hemorrhage or the position of the guide cannula was inaccurate. Thus, data from the remaining 16 rats were analyzed.
In contrast to the PBS group, 1 μg 8-OH-DPAT decreased the duration of GS during SE (P <0.05, Fig.   4A ). However, it did not have any signifi cant effect on the latency to behavioral GS (Fig. 4B) or EEG seizure activity, or the total seizure time ( Table 1) . 
DISCUSSION
In the present study, subcutaneous 8-OH-DPAT delayed the onset of both EEG and behavioral seizure activity and shortened the duration of GSs in a Li-pilocarpine-induced rat model of SE, and these effects were prevented by WAY-100635. These findings support the hypothesis that the activation of 5-HT 1A receptors induces an inhibitory effect on seizure activity [22] [23] [24] . These inhibitory effects on both the generation and severity of SE are consistent with previous reports in KA-induced models of SE [5, 12, 14] . However, these [25, 26] .
Hence, the inhibitory effect of 5-HT 1A receptors might be more evident in the Li-pilocarpine model than in the highdose pilocarpine-only model. Compared with the GSs in SE models, however, the activation of 5-HT 1A receptors does not affect the GSs in fully amygdaloidal kindled rats [12, 27] .
This difference suggests that 5-HT 1A receptors are more effective in seizure generation.
In the present study, low doses of 8-OH-DPAT (0.01 and 0.1 mg/kg) did not alter the seizure activity in SE, differing from the effects of different doses of 8-OH-DPAT in the KA model of SE [12] . A similar situation was found for WAY-100635 administration, which increased the discharge duration at 0.1 mg/kg in hippocampal kindling rats, but reduced subsequent discharges at 0.3 and 1.0 mg/kg [28] . and are present at moderate levels in the amygdaloid nucleus and piriform cortex [6, 29, 30] . Low doses of 8-OH-DPAT (0.1 mg/kg) were found to activate only the pre-synaptic receptors, whereas high doses (1.0 mg/kg) activate both the pre-and the post-synaptic receptors in a study of psychotic-like behavior [31] . Therefore, the present results indicate the possible involvement of post-synaptic receptors in the anticonvulsant effects of this treatment. Activation of 5-HT 1A receptors reduces the bursts in the hippocampal CA1 area in vitro [32] . This inhibitory effect might be primarily correlated with its ability to activate G protein-coupled inward-rectifying potassium channels, which enables them to induce hyperpolarizing currents that suppress neuronal fi ring and excitability [6, 33] . Besides, diminished glutamate release induced by the activation of 5-HT 1A receptors may also be involved in the anticonvulsant effects of 8-OH-DPAT [14, 34] .
I t i s w o r t h n o t i n g t h a t t h e i n t r a h i
However, intrahippocampal activation of 5-HT 1A receptors fails to delay the development of SE in both the Li-pilocarpine and KA models. Subcutaneous 8-OH-DPAT administration in KA-induced SE only suppresses spike frequency in the frontal cortex, but not in the hippocampus [5] , which indicates that a delayed propagation of seizure discharges might occur on the way from the limbic regions to the cortex. 5-HT 1A receptors are also distributed in several important extra-hippocampal sites of the limbic system that are involved in the development of SE, including the EC, the pyriform cortex and the amygdaloid nucleus [6, 18, 35] . The inhibitory effect on seizure propagation could be attributed to the activation of 5-HT 1A receptors within these sites. However, more studies focusing on the direct activation of receptors in these sites are needed to test this hypothesis.
In addition, 8-OH-DPAT may have non-specific effects mediated by activation of 5-HT 7 receptors and α1-adrenergic receptors [23, 24] . Although WAY-100635 is regarded as a specific antagonist of 5-HT 1A receptors, it also affects the dopamine system [36] [37] [38] . Therefore, further experiments are required to explore the possible involvement of these receptors in the effects of 8-OH-DPAT and WAY-100635 on seizure activity.
In conclusion, the activation of 5-HT 1A receptors has an anticonvulsant effect on Li-pilocarpine-induced SE in rats. receptor is a promising therapeutic target against the generation and propagation of seizures in SE.
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